Abstract
Abstract Background The patients with ulcerative colitis (UC) can have low quality of life and their work productivity can be also impaired. The aim of this study is to investigate the work productivity and activity impairment (WPAI) of moderate to severe UC patients with biologics treatment, using the MOSAIK cohort (ClinicalTrials.gov: NCT02229344). Methods In this cohort, we enrolled patients with moderate to severe UC diagnosed for the first time and collected their WPAI questionnaires annually from the time of diagnosis. WPAI questionnaires scored overall work impairment and social activity impairment from 0 to 10. We compared the scores between the patients treated with biologics and without biologics. Results In a total 346 patients, 69 (19.9%) patients started biologics during 5 years of observation period. 43 (12.43%) patients started biologics within 1 year from diagnosis. At baseline, mean score of overall work impairment (10 points scale) in biologics group was higher than that of non-biologics group (4.8 and 3.8, respectively). During the treatment, both groups showed numerical improvement of work productivity and social activity. At 1 year, the difference in scores of work productivity impairment between the two groups decreased to 2.6 and 1.8, respectively. Finally at 5 year, the scores of work productivity impairment were similar in the biologics and non-biologics group (1.5 and 1.4, respectively). Conclusion In moderate to severe UC, the patients receiving biologics due to their high disease activity can experience impaired work productivity. However, work productivity and social activity can be improved in biologics group as much as in the non-biologics group. Therefore, it is important to start biologics timely to control the disease activity and eventually restore the patients’ daily work and life.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call